P3 Health Partners Inc. Q1 FY2026 earnings call

• Strategic Repositioning Milestone: Q1 2026 marks an inflection point for P3, with 24 months of restructured contracts, market optimization, operational redesign, and aligned clinical-financial infrastructure now delivering measurable, non-temporary sustainable profitability, driven by deliberate strategic actions rather than one-time factors. Three core drivers underpinned the quarter's improved performance:
  1. Payer Contract Restructuring: Over 18 months, P3 redesigned risk funding and cost accountability structures across payer and network relationships, resulting in 15% year-over-year Medicare Advantage (MA) funding rate improvement, 63% of 2026 membership covered under delegated functions (up from prior levels), and materially improved alignment across the company's largest payer relationships.
  2. Clinical and Operational Execution: Disciplined investment in medical cost management, quality performance, provider engagement, and risk accuracy has delivered durable results: Tier 1 provider concentration increased from 56% in Q1 2025 to 62% in Q1 2026; burden of illness capture and documentation accuracy are improving; STARS quality performance is tracking ahead of internal targets; the new high-risk complex member program (with 24/7 clinical support to reduce avoidable high-acity care) continues to ramp; MA medical cost trend was roughly flat in Q1 2026, following a full-year 2025 trend below 2% across MA and ACO populations, far below the industry average 7%+ trend guidance; operating expense remains tightly controlled with selective targeted investment in high-impact capabilities.
  3. Favorable Macro Environment: The 2026 CMS benchmark update improved MA market economics, and industry-wide benefit design rationalization has created more sustainable utilization dynamics, favoring providers with strong provider alignment, local operational capabilities, effective cost management, and scalable clinical infrastructure, all of which P3 has prioritized.
• Strategic Prioritization Going Forward: P3 will prioritize markets and payer relationships with a clear path to deeper delegation of core functions (claims payment, utilization management, care management), as delegated control consistently delivers stronger medical cost performance, better quality outcomes, improved member engagement, and improved cash flow and margin predictability. This delegated, integrated operating model is a difficult-to-replicate structural competitive advantage for P3.
• Disciplined Growth Execution: The new Nebraska partnership adding 28,600 managed lives follows this prioritization framework, with implementation remaining on track. This partnership structure addresses key value-based care growth challenges by establishing mutually beneficial cash flow and contractual terms for both P3 and payer partners.
• Balance Sheet Strengthening: Recent capital structure transactions, including conversion of $250 million of debt to preferred equity and issuance of $30 million (with up to $70 million total planned) of additional preferred equity, have brought stockholders' equity above the NASDAQ minimum compliance threshold, materially improving financial flexibility and long-term balance sheet strength.

P3 Health Partners reports aggregate financial results for Q1 2026 without breaking out separate product segments. Key aggregate performance metrics are: Total Q1 2026 revenue of $386 million, up from $373 million in Q1 2025; medical claims expense of $306 million; medical margin of $74 million, with an adjusted medical loss ratio of 85.2% after adjusting for favorable prior year development and payer settlements; adjusted operating expense of $25 million; adjusted EBITDA of $26 million, compared to an adjusted EBITDA loss of $22 million in Q1 2025. Total at-risk membership was 106,000 at end-Q1 2026, down from 118,000 in Q1 2025 due to deliberate exit of non-economic arrangements; an additional 29,000 lives are managed under service agreements, bringing total managed lives to 135,000. Ending cash and equivalents were $25 million as of Q1 2026.

P3 management has upwardly revised its full-year 2026 adjusted EBITDA guidance to a range of $20 million to $60 million, with a midpoint of $40 million. The upward revision reflects the $17 million of favorable prior year development and payer settlements recognized in Q1 2026, as well as management's increased confidence in the company's underlying operating trajectory for the remainder of 2026. Confidence in the outlook is based on continued realization of structural contract improvements, ongoing strong clinical execution for cost and quality management, and maintained operating expense discipline. The wide guidance range reflects normal variability in annual claims development and cost outcomes, with full-year results contingent on actual medical cost trend progression and execution against ongoing medical cost initiatives.

The call notes that all forward-looking statements are inherently uncertain, and actual results could differ materially from current expectations due to unidentified or unanticipated risks, consistent with risk factors disclosed in P3's periodic SEC filings. The only specific operational risk discussed is that medical cost trend variability will impact full-year 2026 results within the stated guidance range. Progress expanding delegated functions beyond the current 63% of membership depends on payer-side internal timelines, required pre-delegation audits, and phased testing, so expansion will be gradual (stair-stepped over two years) rather than immediate, introducing execution timing risk.

Q: What was the Q1 2026 medical cost trend split between Medicare Part A and Part B, and what is the split of the $17 million favorable prior year development (PYD) and payer settlements? Did any portion of the favorable PYD get added back to reserves, or did all of it flow through Q1 results? / A: Q1 2026 saw a larger medical cost reduction in Part B compared to 2025, while Part A trend was predominantly flat year over year. Of the $17 million total favorable item, 65% ($11.05 million) comes from favorable PYD of claims reserves, and 35% ($5.95 million) comes from payer settlements. All $17 million flowed through Q1 2026 results; P3 maintained its consistent reserve methodology and did not adjust existing reserve estimates, so no portion was reallocated back to reserves.

Q: How does P3's improved Q1 performance and recently completed balance sheet strengthening improve the company's position to expand with existing and new payer partners? / A: Demonstrated positive operating momentum and a strengthened, more stable balance sheet do improve P3's position with prospective payer growth partners. A stronger balance sheet directly supports P3's core strategy of expanding delegated function arrangements with payers; deeper delegation improves cash flow timing and acceleration for P3, while also delivering better operational and cost outcomes for payers, making the company a more attractive partner for these high-value arrangements.

Q: What is the pathway to increase delegated membership beyond the current 63% level, and how quickly can this expansion happen? / A: Most of the near-term opportunity to expand delegation is concentrated in one major geography where current delegation levels are very low. P3 has already agreed to contractual glide paths for delegation with all relevant payers in this market, but expansion depends on payer internal timelines, required pre-delegation audits, and phased testing before full delegation is implemented. As a result, delegation expansion will proceed gradually in a stair-step fashion over approximately the next two years, rather than being implemented immediately.